Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pfizer Korea Builds Up Presence Further In Korea Through Merger With Wyeth Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - With the Jan. 29 approval of South Korea's Fair Trade Commission, Pfizer swiftly integrated its operations with Wyeth Korea to become one entity Feb. 1

You may also be interested in...



Korea Labor Unions At Global Pharma Firms Band Together To Protect Jobs

South Korean labor unions at multinational pharma firms such as Novartis and AstraZeneca recently banded together with the common goal of seeking job security as a lackluster business environment prompts layoffs.

Pfizer Will Seek Out More R&D Opportunities in Korea

SEOUL - Pfizer Korea will seek more opportunities for R&D partnerships in Korea as it tries to develop treatments for Asia-prevalent liver and stomach cancers

Pfizer Will Seek Out More R&D Opportunities in Korea

SEOUL - Pfizer Korea will seek more opportunities for R&D partnerships in Korea as it tries to develop treatments for Asia-prevalent liver and stomach cancers

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Tags:
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC074184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By